Pulse Biosciences (PLSE) announced the first successful procedures in a multicenter IRB-approved study using Pulse Biosciences’ nsPFA Percutaneous Electrode System for the treatment of benign thyroid nodules.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE:
- Pulse Biosciences’ Earnings Call: Clinical Gains and Financial Hurdles
- Pulse Biosciences Publishes Promising Thyroid Study Results
- Pulse Biosciences publishes benign thyroid nodules data in Journal Thyroid
- Pulse Biosciences Reports Q2 2025 Progress and Results
- Pulse Biosciences Appoints New VP of Accounting